Search results for "coagulation"

showing 10 items of 381 documents

Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor.

2006

Hereditary angioedema is characterized by recurrent skin swelling, abdominal pain attacks, and potentially life-threatening upper airway obstruction. The two classic types are both caused by mutations within the complement C1 inhibitor gene. A recently described new type does not show a deficiency of C1 inhibitor and affects almost exclusively women. We screened twenty unrelated index patients with this new type of hereditary angioedema for mutations in the coagulation factor XII gene. Two different missense mutations were identified in exactly the same position within exon 9 of the F12 gene. 'Mutation 1' (1032C-->A), encountered in five patients, predicts a threonine-to-lysine substitution…

Malemedicine.medical_specialtyGenetic LinkageBiophysicsMutation MissenseCoagulation Factor XIImedicine.disease_causeBiochemistryC1-inhibitorInternal medicinemedicineMissense mutationHumansHereditary Angioedema Type IIIAngioedemaMolecular BiologyMutationFactor XIIAngioedemabiologyChemistryCell Biologymedicine.diseasePedigreeEndocrinologyHereditary angioedemaImmunologyFactor XIIbiology.proteinFemalemedicine.symptomComplement C1 Inhibitor ProteinBiochemical and biophysical research communications
researchProduct

Hereditary Angioedema with Normal C1 Inhibitor

2013

Until recently it was assumed that hereditary angioedema was a disease that results exclusively from a genetic deficiency of the C1 inhibitor. In 2000, families with hereditary angioedema, normal C1 inhibitor activity, and protein in plasma were described. Since then, numerous patients and families with that condition have been reported. Most of the patients were women. In many of the affected women, oral contraceptives, hormone replacement therapy containing estrogens, and pregnancies triggered the clinical symptoms. In some families mutations in the coagulation factor XII (Hageman factor) gene were detected.

Malemedicine.medical_specialtyImmunologyCoagulation Factor XIIC1-inhibitorDiagnosis DifferentialPregnancyRisk FactorsInternal medicinemedicineHumansImmunology and AllergyHereditary Angioedema Type IIIAngioedemaFactor XIIbiologyAngioedemabusiness.industryAngioedemas Hereditarymedicine.diseaseEndocrinologyTransgender hormone therapyFactor XIIMutationHereditary angioedemabiology.proteinFemaleDifferential diagnosismedicine.symptombusinessComplement C1 Inhibitor ProteinImmunology and Allergy Clinics of North America
researchProduct

Murine tissue factor disulfide mutation causes a bleeding phenotype with sex specific organ pathology and lethality.

2019

Tissue factor is highly expressed in sub-endothelial tissue. The extracellular allosteric disulfide bond Cys186-Cys209 of human tissue factor shows high evolutionary conservation and in vitro evidence suggests that it significantly contributes to tissue factor procoagulant activity. To investigate the role of this allosteric disulfide bond in vivo, we generated a C213G mutant tissue factor mouse by replacing Cys213 of the corresponding disulfide Cys190-Cys213 in murine tissue factor. A bleeding phenotype was prominent in homozygous C213G tissue factor mice. Pre-natal lethality of 1/3rd of homozygous offspring was observed between E9.5 and E14.5 associated with placental hemorrhages. After b…

Malemedicine.medical_specialtyOffspring610 Medicine & healthHemorrhage030204 cardiovascular system & hematologyBiologymedicine.disease_causeArticleThromboplastin11459 Center for Molecular Cardiology03 medical and health sciencesTissue factorArterial Thrombosis; Blood Coagulation and Fibrinolysis; Disorders of Coagulation and FibrinolysisMice0302 clinical medicineIn vivoPregnancyInternal medicinemedicineExtracellularAnimalsDisulfidesMutationHematologyPhenotypeIn vitroEndocrinologyPhenotype10036 Medical Clinic10076 Center for Integrative Human PhysiologyHemostasisMutation10209 Clinic for CardiologyFemale030215 immunologyHaematologica
researchProduct

Boy with pseudohypoparathyroidism type 1a caused byGNASgene mutation (deltaN377), Crouzon-like craniosynostosis, and severe trauma-induced bleeding

2009

We report on a 6-month-old boy with craniosynostosis, pseudohypoparathyroidism type 1a (PHP1A), and a GNAS gene mutation. He had synostoses of the coronal, frontal, and sagittal sutures, brachyturricephaly, and hydrocephaly. He also had congenital hypothyroidism, round face, full cheeks, shortness of limbs, mild developmental delay, and muscular hypotonia. Because of progressive hydrocephaly, the synostosis was corrected surgically but circulatory decompensation led to disseminated intravascular coagulation and cerebral infarctions. Our patient died 8 days later. Postmortem molecular studies of GNAS, the gene for guanine nucleotide-binding protein, alpha-stimulating activity polypeptide (ge…

Malemedicine.medical_specialtyPathologyCraniosynostosisFatal OutcomeInternal medicineChromograninsCongenital HypothyroidismGTP-Binding Protein alpha Subunits GsGeneticsmedicineGNAS complex locusHumansGenetic Predisposition to DiseaseGenetics (clinical)PseudohypoparathyroidismDisseminated intravascular coagulationbiologyMuscular hypotoniabusiness.industryCraniofacial DysostosisInfantDysostosisSynostosismedicine.diseaseCongenital hypothyroidismEndocrinologyBrain InjuriesPseudohypoparathyroidismMutationbiology.proteinbusinessIntracranial HemorrhagesHydrocephalusAmerican Journal of Medical Genetics Part A
researchProduct

Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy

2009

SUMMARY BACKGROUND: More and more people with severe hemophilia reach an old age thanks to an effective treatment. There is no information on the health status and quality of life of elderly people with hemophilia born at a time when replacement therapy was hardly available. METHODS: Italian patients with severe hemophilia, aged >or=65 years and hence born in 1942 or earlier, were compared with elderly men without bleeding disorders matched for age, sex, geography and social status. The following aspects were evaluated: concomitant illness, orthopedic status, physical functioning and cognitive status. Measurements of generic and disease-specific health-related quality of life were also obta…

Malemedicine.medical_specialtyPediatricshamophilia healt status agingActivities of daily livingHealth StatusPopulationActivities of Daily Living; Aged; Blood Coagulation Factors; Hemophilia A; Humans; Italy; Male; Health Status; Quality of LifeHemophilia ASettore MED/15 - Malattie Del SangueQuality of lifehemic and lymphatic diseasesArthropathyActivities of Daily LivingMedicineHumanseducationDepression (differential diagnoses)Agededucation.field_of_studybusiness.industryHematologymedicine.diseaseBlood Coagulation FactorsItalyConcomitantOrthopedic surgeryPhysical therapyQuality of LifebusinessSocial status
researchProduct

Temporal retrogasserian resection of trigeminal root versus controlled elective percutaneous electrocoagulation of the ganglion of gasser in the trea…

1972

In his experience with 531 surgical procedures for the relief of trigeminal neuralgia between 1955 to 1970, the author developed a strong preference for the percutaneous electro-coagulation of the gasserian ganglion. Although the method was repeatedly modified in the early years, a standardized technique of controlled, selective and fractional coagulation in the semiawake state of neurolept-anaesthesia was used since 1963 in 183 of his 311 patients, treated in this manner. The advantages of the method, particularly in comparison to open intracranial root sections, are: Minimal operative risk, control of operative effect during the operation, small sensibility deficit, low rate of complicati…

Malemedicine.medical_specialtyPercutaneousmedicine.medical_treatmentmedia_common.quotation_subjectElectrocoagulationStereotaxic TechniquesThalamusTrigeminal neuralgiaMesencephalonmedicineElectrocoagulationMethodsHumansTrigeminal Nervemedia_commonNeuroradiologyMedulla Oblongatamedicine.diagnostic_testbusiness.industryConvalescenceInterventional radiologyTrigeminal Neuralgiamedicine.diseaseSurgeryGanglionmedicine.anatomical_structureEvaluation Studies as TopicAnesthesiaSurgeryNeurology (clinical)NeurosurgerybusinessCraniotomyActa neurochirurgica
researchProduct

Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation

2008

Aims: To gain insight in the prognosis and treatment of atrial fibrillation (AF) patients during 1-year follow-up in the Euro Heart Survey (EHS) on AF. Methods and results: The EHS enrolled 5333 AF patients in 2003-2004. One-year follow-up data were available for 80%. Of first detected AF patients, 46% did not have a recurrence during 1 year, paroxysmal AF largely remained paroxysmal AF (80%), and 30% of persistent AF progressed to permanent AF. Many treatment changes occurred since baseline. Oral anticoagulation was started in 19% and discontinued in 16% of all patients. Of patients initially on rhythm control 27% did not receive rhythm control during follow-up, whereas 15% of patients ini…

Malemedicine.medical_specialtyRate controlHeart DiseasesHeart diseasePrognosiHemorrhageRisk AssessmentAnticoagulationElectrocardiographyInternal medicineAtrial FibrillationHumansMedicineSinus rhythmProspective StudiesMortalityProspective cohort studyStrokeSurvival rateAgedProgressionmedicine.diagnostic_testbusiness.industryAnticoagulantAnticoagulantsAtrial fibrillationPrognosismedicine.diseaseManagementStrokeSurvival RateProspective StudieHeart DiseaseTreatment OutcomeHeart failureDisease ProgressionCardiologyRhythm controlFemaleCardiology and Cardiovascular MedicinebusinessElectrocardiographyHumanEuropean Heart Journal
researchProduct

Androgen receptor assays in specimens of prostatic tissue obtained by transurethral resection and transvesical adenomectomy

1991

The main goal of this study was to ascertain whether routine transurethral resection (TUR) of prostate may provide useful material for the evaluation of androgen receptor (AR) status. At the same time, either intracellular distribution of binding affinity and capacity of receptor molecules were particularly taken into account. Based on our previous findings in breast and endometrial cancer, we suggest that a "functional" receptor status may correspond to the presence of type I (high affinity, low capacity) AR in both soluble and nuclear fractions. However, the precise significance of type II (lower affinity, higher capacity) binding sites remains to be clarified. Ten samples of large prosta…

Malemedicine.medical_specialtyReceptor StatusUrologymedicine.medical_treatmentProstatic HyperplasiaUrologySpecimen HandlingRadioligand AssayProstateInternal medicineElectrocoagulationmedicineRadioligandHumansMiboleroneReceptorProstatectomyChemistryEndometrial cancerProstatemedicine.diseaseIn vitroAndrogen receptorEndocrinologymedicine.anatomical_structureReceptors AndrogenUrological Research
researchProduct

Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicentre Italian CORIST Study

2021

Abstract Introduction A hypercoagulable condition was described in patients with coronavirus disease 2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing to disease progression and lethality. Aim We evaluated if in-hospital administration of heparin improved survival in a large cohort of Italian COVID-19 patients. Methods In a retrospective observational study, 2,574 unselected patients hospitalized in 30 clinical centers in Italy from February 19, 2020 to June 5, 2020 with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 infection were analyzed. The primary endpoint in a time-to event analysis was in-hospital death, comparing patients who receive…

Malemedicine.medical_specialtySettore MED/17 - Malattie Infettivecoronavirusheparin030204 cardiovascular system & hematologyLower risklaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineClinical endpointmedicineHumansThrombophilia030212 general & internal medicineHospital MortalityBlood CoagulationSurvival analysisAgedRetrospective Studiestreatmentbusiness.industryHeparinMortality rateCOVID-19mortalityLow-Molecular-WeightAnticoagulantsCOVID-19Retrospective cohort studyHeparinHematologyHeparin Low-Molecular-WeightMiddle AgedmortalitySurvival AnalysisCOVID-19 Drug Treatmentcoagulation activationcoronaviruItalytreatmentsPropensity score matchingcoagulation activation; coronavirus; COVID-19; heparin; mortality; treatmentsFemalecoagulation activation; coronavirus; COVID-19; heparin; mortality; treatments; Aged; Anticoagulants; Blood Coagulation; COVID-19; Female; Heparin; Heparin Low-Molecular-Weight; Hospital Mortality; Humans; Italy; Male; Middle Aged; Retrospective Studies; Survival Analysis; Thrombophiliabusinessmedicine.drug
researchProduct

Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion.

2002

Abstract Background: Beneath its lipid-lowering properties additional non-lipid effects of statin therapy are discussed. We therefore examined the impact of statins on laboratory markers of coagulation, inflammation and soluble cell adhesion to further explore these effects in 950 hospitalised patients with angiographically proven CAD. Methods and results: Although no significant differences were found in total cholesterol, LDL and HDL and triglyceride levels a statistically lower value in 277 statin-treated patients was found for von Willebrand factor [162(130/224) vs. 208(154/283)%, P =0.0001], leukocyte count [6.9(5.8/8.4) vs. 7.3(6.1/9.4)/nl, P =0.0005], high sensitive CRP [4.3(1.8/10.8…

Malemedicine.medical_specialtyStatinmedicine.drug_classInflammationCoronary Artery DiseaseSystemic inflammationchemistry.chemical_compoundVon Willebrand factorInternal medicinevon Willebrand FactormedicineCell AdhesionHumansAgedbiologyTriglycerideCholesterolbusiness.industryAnticholesteremic AgentsCholesterol LDLMiddle AgedEndocrinologyCoagulationchemistryHMG-CoA reductasebiology.proteinFemalemedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkersInternational journal of cardiology
researchProduct